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http://dx.doi.org/10.1016/j.stemcr.2017.02.015SUMMARYHepatic steatosis is a highly prevalent liver disease, yet research is hampered by the lack of tractable cellular and animal models.
Steatosis also occurs in cats, where it can cause severe hepatic failure. Previous studies demonstrate the potential of liver organoids
for modeling genetic diseases. To examine the possibility of using organoids to model steatosis, we established a long-term feline
liver organoid culture with adult liver stem cell characteristics and differentiation potential toward hepatocyte-like cells. Next,
organoids from mouse, human, dog, and cat liver were provided with fatty acids. Lipid accumulation was observed in all organoids
and interestingly, feline liver organoids accumulated more lipid droplets than human organoids. Finally, we demonstrate effects
of interference with b-oxidation on lipid accumulation in feline liver organoids. In conclusion, feline liver organoids can be
successfully cultured and display a predisposition for lipid accumulation, making them an interesting model in hepatic steatosis
research.INTRODUCTION
A specific adult liver stem cell population acting as second
line of defense in liver regeneration has been described in
several species, including rodents, humans, canines, and
felines (Wang et al., 2003; Roskams et al., 2003; Kruitwagen
et al., 2014; Ijzer et al., 2009). Recently, a three-dimensional
and highly proliferative organoid culture systemwas devel-
oped for mouse, human, and dog liver stem cells (Huch
et al., 2013, 2015; Nantasanti et al., 2015). Liver organoids
have been proposed as in vitro disease-modeling tool for
several genetic liver diseases, such as a1-antitrypsin defi-
ciency, Alagille syndrome, and canine copper storage dis-
ease (Huch et al., 2013, 2015; Nantasanti et al., 2015). How-
ever,many liver diseases do not havemonogenetic etiology
and have a more complex pathophysiology. We aimed to
explore the potential of liver organoids to model non-
genetic metabolic liver disease.
One of the most common metabolic liver diseases in hu-
mans is liver steatosis, also known as non-alcoholic fatty
liver disease (NAFLD) (Younossi et al., 2016). Interestingly,
a severe type of hepatic steatosis also occurs in cats (feline
hepatic lipidosis, FHL) (Center et al., 1993). Both in human822 Stem Cell Reports j Vol. 8 j 822–830 j April 11, 2017 j ª 2017 The Auth
This is an open access article under the CC BY-NC-ND license (http://creativand feline steatosis, hepatocyte lipid overload arises from
an increased amount of free fatty acids (FFA) that are
offered to the liver, and obesity and insulin resistance are
known risk factors for its development (Center, 2005;
Cohen et al., 2011). NAFLD can result in hepatocyte degen-
eration and inflammation (non-alcoholic steatohepatitis),
and ultimately in excessive liver fibrosis and hepatocellular
carcinoma (Cohen et al., 2011).
We asked whether liver organoids could be used tomodel
hepatic steatosis and if so, whether there would be species
differences in hepatocyte lipid-handling capacity. We hy-
pothesized that liver cells from cats could have pronounced
lipid accumulation properties. For this purpose, a culture
system of feline liver progenitor cells as three-dimensional
organoids was established from cat liver samples. First, we
describe the isolation, long-term culture, and characteriza-
tion of feline liver organoids. Second, we investigate the
potential of liver organoids to model hepatic steatosis
and compare lipid accumulation capacity between organo-
ids of mouse, human, dog, and cat liver. Third, as proof of
principle we show the effects of interference with b-oxida-
tion on lipid accumulation and viability in feline liver
organoids.or(s).
ecommons.org/licenses/by-nc-nd/4.0/).
RESULTS
Establishment of the Feline Liver Organoid Culture
Organoids were successfully cultured from cat liver sam-
ples of different origin (i.e., fresh, frozen, and fine-needle
aspirate [FNA]) (Figure 1A). Biliary duct fragments were
observed in the supernatant after digestion (Figure 1B). Af-
ter 3–6 days in culture, spherical structures appeared with
occasional folding and budding. Morphology and passage
rate were similar between donors and tissue sources. It
was even possible to culture organoids from an undigested
FNA plated straight intoMatrigel; organoids appeared after
5 days, emerging from the remnant liver tissue fragments
(Figure 1C). Organoid morphology remained similar be-
tween passages (p1 to p25, Figure 1D). Feline liver organo-
ids could be cultured in expansion medium as published
for mouse, dog, and human liver organoids with varying
success rates on short- and long-term culture (Figure S1)
(Huch et al., 2013, 2015; Nantasanti et al., 2015). However,
a hybridmedium (hereafter named cat expansionmedium)
performed best and allowed for a high split ratio (1:11) in
long-term culture. It was possible to cryopreserve feline
liver organoids as fragments, which formed organoids
again upon thawing.
Characterization of Feline Liver Organoids
We observed feline liver organoids microscopically as
spherical structures with occasional folding and intralumi-
nal epithelial projections (Figure 2A). They were composed
of single-layered cubical epithelium and stained positive
for the epithelial marker E-cadherin (Figure 2A). When
pulsed with 5-ethynyl-20-deoxyuridine (EdU) for 6 hr,
16.4% ± 8.1% of organoid nuclei had incorporated the
thymidine analog (S phase of cell cycle, representative im-
age shown in Figure 2A). Gene expression analysis indi-
cated that feline liver organoids expressed adult stem cell
markers LGR5, PROM1, and BMI1 (Figure 2B). Feline liver
organoids expressed hepatic progenitor cell/biliarymarkers
KRT7 (Ijzer et al., 2009), KRT19, andHNF1b, as well as early
hepatocyte specification markers HNF4a and TBX3 and
very low levels ofALB. Genes ofmature hepatocytemarkers
PROX1, PC, HMGCL, TTR, FAH, and CYP3A132 were ex-
pressed but at low levels compared with normal cat liver.
Gene expression patterns remained stable throughout the
culture. At protein level, feline liver organoids were 100%
positive for K19 (strong cytoplasmic staining), HNF1b
(moderate to strong nuclear staining), and self-renewal
marker BMI1 (moderate to strong nuclear staining) (Fig-
ure 2C). Feline liver organoids were mainly negative for al-
bumin immunoreactivity, but in many organoids a weak
cytoplasmic staining was observed in small clusters of cells
within single organoids. All organoids were negative for
mature hepatocyte marker HepPar-1. Feline liver organoidswere mainly negative for ZO1, but in some organoids a
weak membranous staining was observed in small clusters
of cells within single organoids. Metaphase spread analysis
showed a normal chromosome count in low and high pas-
sages, indicating long-term genetic stability of the cells
similarly to liver organoids from other species (Figure 2D;
Huch et al., 2013, 2015; Nantasanti et al., 2015).
Differentiation of Organoids toward Hepatocyte-like
Cells
Upon culture in differentiation medium, gene expression
of mature hepatocyte markers FAH, CYP3A132, and TTR
increased compared with expansion-medium conditions,
while expression of adult stem cell marker LGR5 decreased
(Figure 3A). Keratin-19 immunoreactivity changed from a
strong cytoplasmic to a moderate membranous staining,
indicative of an ‘‘intermediate hepatocyte’’ phenotype
(Figure 3B; Roskams et al., 2004). BMI1 immunoreactivity
changed from a moderate-strong nuclear staining in
expansion-medium conditions to a weak nuclear staining
in differentiation-medium conditions. ZO1 staining
increased in differentiated feline liver organoids, as more
cells were positive in differentiation-medium compared
with expansion-medium conditions. Organoids in differ-
entiationmedium, but not in expansionmedium, accumu-
lated glycogen as indicated by positive PAS staining. Hep-
Par1 staining was not observed upon differentiation (data
not shown). Proliferation ceased abruptly after switching
organoids from expansion medium to differentiation me-
dium (Figure 3C). Hepatocyte function testing revealed
increased aspartate aminotransferase levels, albumin secre-
tion into themedium, and CYP450 activity in organoids in
differentiation-medium conditions compared with expan-
sion-medium conditions (Figure 3D).
Feline Liver Organoids for Disease Modeling of
Hepatic Steatosis
To investigate liver organoids as a potential in vitro model
for steatosis, wemimicked circumstances of excess FFA con-
centrations and measured intracellular lipid accumulation
with the lipophilic dye LD540 using flow cytometry (Fig-
ure S2). We compared organoids from mouse, human,
dog, and cat liver (four donors each) to assess species differ-
ences in lipid accumulation capacity. Median fluorescence
intensity of LD540 was quantified in liver organoid cells af-
ter either control (BSA) or FFA treatment. For all four spe-
cies, an increase in LD540 median fluorescence intensity
was observed after FFA treatment compared with control,
indicating intracellular lipid accumulation (Figure 4A).
When this increasewas compared between species, cat liver
organoids showed more lipid accumulation than human
liver organoids after FFA treatment (192 ± 104 versus 61 ±
36, p = 0.029). LD540-positive intracellular lipid dropletsStem Cell Reports j Vol. 8 j 822–830 j April 11, 2017 823
Figure 1. Establishment of an Organoid Culture from Feline Liver Samples
(A) Fresh and snap-frozen liver samples (wedge biopsies of 5 mm3) could be used with equal success rate to establish an organoid culture.
It was also possible to start a feline liver organoid culture from a fine-needle aspirate (aspirate visible in the conus of the needle).
(B) Representative phase-contrast images of duct isolation and organoid culture. After enzymatic digestion of feline liver samples, biliary
duct fragments (arrow) were observed (scale bar represents 50 mm). Ducts were cultured in Matrigel and defined medium. After
approximately 3 days in culture (d3), spherical structures appeared that rapidly grew out to large organoids within 6 days (d6) (scale bars
represent 100 mm).
(C) Representative phase-contrast image of an undigested fine-needle aspirate (FNA) plated straight into Matrigel. After 5 days, organoids
emerged from the remnant liver tissue fragments. Scale bar represents 100 mm.
(D) Representative phase-contrast images of feline liver organoids in early, medium, and late passages (p1, p12, and p25). Morphology
remained similar during long-term culture. Scale bars represent 100 mm.
See also Figure S1.were visualized in whole-mount immunofluorescent stain-
ings of mouse, human, dog, and cat liver organoids after
FFA treatment (representative images shown in Figure 4B).824 Stem Cell Reports j Vol. 8 j 822–830 j April 11, 2017Transcriptional analysis of human and cat liver organoids
treated with FFA indicated that in both species PLIN2
was upregulated, consistent with increased lipid-droplet
Figure 2. Characterization of Feline Liver
Organoids
(A) Representative cytological and immuno-
fluorescent images of feline liver organoids.
H&E staining showed that organoids con-
sisted of single-layered cubical epithelium.
They stained positive for epithelial marker
E-cadherin (green) and were highly prolifer-
ative in culture as shown by EdU staining
(green, marks S phase of the cell cycle). DAPI
(blue) was used as nuclear counterstain.
(B) Gene expression analysis of feline liver
organoids (n = 4 donors) in different passages
(p2, p8, p14) and normal cat liver. Relative
gene expression (expr.) is shown of adult
stem cell, progenitor/biliary, and early and
mature hepatocyte markers.
(C) Representative images of immunocyto-/
histochemical stainings of feline liver orga-
noids and normal cat liver. Organoids stained
positive for progenitor/biliary markers K19,
HNF1b, and BMI1. They stained negative for
hepatocyte marker HepPar-1, but for albumin
and ZO1 small clusters of cells within single
organoids stained positive (indicated by ar-
rowheads and arrows, respectively).
(D) Karyotyping of feline liver organoids.
A representative metaphase spread is shown
of a cell with a normal chromosome number
(n = 38). Chromosome counts were compared
between low- and high-passage number cul-
tures (p3–p7 versus p16–p23, n = 4 donors
per category) and plotted as percentage
of cells with a normal chromosome number
(n = 38), one gain (n = 39), one loss (n = 37),
or two or more losses (n% 36).
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Figure 3. Differentiation of Feline Liver Organoids toward Hepatocyte-like Cells
(A) Relative gene expression of feline liver organoids cultured in expansion medium (EM) and differentiation medium (DM) (n = 4 donors).
*p < 0.05, Mann-Whitney U test.
(B) Representative images of immunocytochemical stainings for K19, BMI1, and ZO1 and PAS staining (indicating glycogen accumulation)
of feline liver organoids cultured in EM and DM.
(C) Growth curve derived from an Alamar blue assay of feline liver organoids cultured in EM and DM for 7 days (n = 4 donors). Proliferation is
presented as percentage relative to measurement at day 0. Error bars indicate SD.
(D) Hepatocyte function tests of feline liver organoids cultured in EM and DM (n = 4 donors). Aspartate aminotransferase (AST) levels,
albumin secretion in the medium, and CYP450 activity were corrected for cell input with Alamar blue. *p < 0.05, Mann-Whitney U test.formation (Figures 4C and S3). SREBF1, a transcription fac-
tor that induces de novo lipogenesis, was decreased in hu-
man and feline organoids. FFA-treated feline organoids
increased their expression of CPT1A (a key enzyme in
b-oxidation) and PPARG, a transcription factor known
to enhance b-oxidation. Both genes were unchanged in
human organoids. In human organoids, FFA treatment
decreased expression of PPARA and its downstream targets
ACADSB and AGPAT2. Next, we studied the effects of either
etomoxir or L-carnitine supplementation compared with826 Stem Cell Reports j Vol. 8 j 822–830 j April 11, 2017FFA treatment alone on lipid accumulation and viability
in feline liver organoids. Etomoxir, a carnitine palmitoyl-
transferase-1 inhibitor, blocks the transfer of FFA over the
mitochondrial membrane (carnitine shuttle), preventing
them from entering b-oxidation. Conversely, L-carnitine
is an essential co-factor for the carnitine shuttle. In feline
liver organoids, FFA treatment decreased viability of the
cells compared with BSA control (86% ± 2% versus 96% ±
2%, p = 0.034) (Figure 4D); morphologically, the organoids
gained a dark appearance (Figure 4E). Lipid accumulation
Figure 4. Liver Organoids for Disease Modeling of Hepatic Steatosis
(A) Lipid accumulation in liver organoids frommouse, human, dog, and cat (n = 4 donors per species). Intracellular lipids were stained with
LD540 and fluorescence was quantified using flow cytometry (see also Figure S2). Data are presented as a dot plot and indicate the increase
in LD540 median fluorescence intensity after free fatty acid (FFA) treatment compared with control treatment with BSA. *p < 0.05, Mann-
Whitney U test.
(B) Representative immunofluorescent images of LD540 staining of mouse, human, dog, and cat liver organoids after control treatment
(BSA) and FFA treatment. Intracellular lipid droplets stain green, nuclei are counterstained with DAPI (blue).
(C) Heatmap representing the transcriptional analysis of human and cat liver organoids treated with FFA compared with control treatment
(BSA). Red indicates decreased gene expression, black unchanged gene expression, and green increased gene expression. See also Figure S3.
(D) Lipid accumulation in feline liver organoids treated with control (BSA), FFA, FFA plus etomoxir, and FFA plus L-carnitine. Intracellular
lipid accumulation (left) was quantified with flow cytometry and plotted as LD540 median fluorescence intensity for each individual donor
(cats 1, 2, 3, 4; *p < 0.05, Wilcoxon signed-rank test). Cellular viability after treatment (right) was measured using a trypan blue assay
(*p < 0.05, Wilcoxon signed-rank test).
(E) Representative phase-contrast images of feline liver organoids treated with control (BSA), FFA, FFA plus etomoxir, and FFA plus
L-carnitine.
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increased with the FFA + etomoxir combination compared
with FFA treatment alone (253 ± 69 versus 176 ± 56,
p = 0.034), and organoid viability decreased (82% ± 3%
versus 86% ± 2%, p = 0.034). On the other hand, lipid accu-
mulation decreased with FFA + carnitine supplementation
compared with FFA treatment alone (146 ± 39 versus 176 ±
56, p = 0.034), with an increase in organoid viability
(90% ± 3% versus 86% ± 2% p = 0.034). The morphology
of the organoids treated with FFA + carnitine was more
comparable with the BSA control thanwith the FFA-treated
organoids, indicating that L-carnitine may help alleviate
the surplus.DISCUSSION
In the present study, long-term genetically stable feline
liver organoid cultures were established and extensively
characterized. To our knowledge, the liver organoids
described in this study are the only available primary
non-transformed long-term cell culture system from cats.
Feline liver organoids retain characteristics similar to
liver organoids of other species, including massive prolifer-
ation capacity, an epithelial nature, and their gene expres-
sion pattern (Huch et al., 2013, 2015; Nantasanti et al.,
2015). Feline liver organoids were positive for progenitor/
biliary markers as well as early hepatocyte specification
markers, indicative of a hepatic progenitor cell phenotype
(Roskams et al., 2003). In addition, in some parts or cell
clusters within single organoids albumin or ZO1 was ex-
pressed, whereas the rest of the structurewas negative, indi-
cating that there are different maturation levels within an
organoid. This has also been described for mouse small in-
testinal organoids, which harbor a crypt and villus domain
representative of a stem cell pool and a more mature prog-
eny, respectively (Sato et al., 2009).
Feline liver organoid differentiation was associated
with an abrupt cease in proliferation, a phenomenon also
observed in cultures of primary hepatocytes, which cannot
be expanded and rapidly dedifferentiate in vitro (Fraczek
et al., 2013). Although feline liver organoids showed a
higher expression of liver-specific genes and had increased
albumin secretion and aspartate aminotransferase and
CYP3A activity upon differentiation, they did not reach
fullmaturation (e.g., they remainednegative forHepPar-1).
Until now it has not been possible to accomplish full hepa-
tocyte maturation in vitro from an immature cell type,
such as embryonic stem cells or induced pluripotent stem
cells (Ochiya et al., 2010; Zhang et al., 2013), nor to main-
tain maturation status of primary hepatocytes in culture
(Fraczek et al., 2013). Future research is needed to elucidate
pathways that are important for terminal differentiation of
hepatocytes.828 Stem Cell Reports j Vol. 8 j 822–830 j April 11, 2017We compared several liver organoid species (mouse, hu-
man, dog, and cat), and in all observed lipid accumulation
when liver organoids were provided with FFA. Oleate and
palmitate represent the most abundant fatty acid species
in healthy and steatotic human and cat liver (Araya et al.,
2004; Fujiwara et al., 2015). Hence, oleate and palmitate
are widely used in lipidomics research and are considered
physiologically relevant for modeling hepatic lipid accu-
mulation (Go´mez-Lecho´n et al., 2007). Hepatocytes have
three major routes to handle FFA. They can (1) enter
b-oxidation to provide energy or a substrate for ketogen-
esis, or they can be re-esterified to triglycerides, and either
(2) become excreted in very-low-density lipoproteins
(VLDL) or (3) be stored as intracellular lipid droplets. There
were marked species differences in the extent of lipid accu-
mulation on a cellular level: feline liver organoids accumu-
lated more lipids than did human liver organoids. This
exaggerated phenotype of lipid overload in feline liver cells
complies with the fact that steatosis in cats often leads to
liver failure and severe disease (Center, 2005). We can spec-
ulate that the other metabolic pathways handling excess
FFA (b-oxidation, VLDL secretion) are quickly saturated in
feline hepatocytes, leading to extensive lipid-droplet for-
mation. Both human and feline organoids upregulated
PLIN2 expression after FFA treatment, an essential machin-
ery protein in lipid accumulation in lipid droplets.
However, we also observed differences in transcriptional
activation between human and feline organoids after FFA
treatment, which could be explained by differences in acti-
vation of essential lipid regulatory pathways (mainly via
PPARA and PPARG). Future researchmight focus on species
differences in PPARA and PPARG signaling in response
to excess FFA and their effects on hepatocellular lipid catab-
olism and storage.
To further explore the value of feline liver organoids as a
research model for steatosis, we tested the effect of small
molecules on lipid metabolism. Lipid accumulation was
enhanced in the presence of etomoxir, indicating that
b-oxidation is an important metabolic pathway handling
excess fatty acids in feline liver cells. Conversely, supple-
mentation of L-carnitine of feline liver organoids attenu-
ated lipid accumulation in high-fat conditions and
improved cellular viability. This is in concordance with
the finding that exogenous L-carnitine supplementation
can ameliorate FFA oxidation in cats with FHL (Center
et al., 2012). The possibility to interfere in vitro with orga-
noid lipid accumulation offers opportunities to test new
drugs that enhance b-oxidation or promote VLDL secre-
tion, with the aim of eliminating superfluous triglycerides
from hepatocytes in vivo.
In conclusion, we describe a long-term three-dimen-
sional primary culture of feline liver organoids, and
demonstrate that they retain characteristics of adult liver
stem cells and are highly similar to liver organoids of other
species. The pronounced phenotype of lipid accumulation
in feline liver organoids compared with organoids from
other species reveals remarkable species differences in
cellular lipid-handling capacity. Hence, feline liver organo-
ids represent an in vitro magnifying glass to investigate the
molecular underpinnings of fatty liver disease and can
become a valuable research tool to explore new therapeutic
strategies for hepatic steatosis.EXPERIMENTAL PROCEDURES
Liver Samples
Surplus liver samples were obtained postmortem from five cats
(two female, three male); no animals were harmed or killed for
the purpose of this study. Sample handling is further described
in Supplemental Experimental Procedures.
Mouse (n = 4 donors) and dog (n = 4 donors) liver organoid cul-
tures were generated as described earlier from surplus livermaterial
harvested from animals in non-liver-related research (experiments
approved by the Utrecht University’s ethical committee) (Huch
et al., 2013; Nantasanti et al., 2015).
Human (n = 4 donors) liver organoid cultures were generated as
described earlier from surplusmaterial of donor livers used for liver
transplantations performed at the ErasmusMedical Center, Rotter-
dam (approved by theMedical Ethical Council of the ErasmusMC)
(Huch et al., 2015).
Isolation of Biliary Ducts and Feline Liver Organoid
Culture
Liver wedge biopsies were minced with scalpel blades and washed
in DMEM medium with 1% (v/v) fetal calf serum and 1% (v/v)
penicillin-streptomycin (all from Gibco). Samples were enzymati-
cally digested with 0.3 mg/mL type II collagenase (Gibco) and
0.3 mg/mL dispase (Gibco) at 37C for 2–3 hr and triturated every
20min. Supernatant was checked for biliary duct fragments. Super-
natantwas centrifuged at 803 g for 5min at 4Cand pelleted ducts
were mixed with cold Matrigel (BD Biosciences). The FNAmaterial
was washed, but not minced nor digested before mixing with Ma-
trigel. Matrigel suspension was seeded as droplets in 48- or 24-well
plates and allowed to solidify at 37C before overlaying with cul-
ture medium. Expansion medium as published for mouse, dog,
and human liver organoids was tested on feline liver organoids
(Huch et al., 2013, 2015; Nantasanti et al., 2015). Medium effects
on organoid proliferation were evaluated over the short term
(1-week growth curve) with an Alamar blue assay according to
the manufacturer’s instructions (Life Technologies). Medium ef-
fects on organoid expansion in long-term culture were derived
fromweekly split ratios. Based on the obtained results (see also Fig-
ure S1), a newmedium composition was developed (cat expansion
medium [cEM]), which was a hybrid between dog and human
expansionmedia. cEM consisted of Advanced DMEM/F12, supple-
mented with 1% (v/v) penicillin-streptomycin, 1% (v/v) Gluta-
Max, 10 mM HEPES (all Gibco), 2% (v/v) B27 minus vitamin A
(Invitrogen), 1% N2 (Invitrogen), 10 mM nicotinamide (Sigma-
Aldrich), 1.25 mM N-acetylcysteine (Sigma-Aldrich), 5% (v/v)R-spondin-1 conditioned medium (the Rspo1-Fc-expressing cell
line was a kind gift from Calvin J. Kuo), 10 mM forskolin (Sigma-
Aldrich), 10 mM Y-27632 (ROCK inhibitor, Selleckchem), 0.5 mM
A83-01 (transforming growth factor b inhibitor, Tocris Bioscience),
50 ng/mL EGF (Invitrogen), 25 ng/mLHGF (Peprotech), 0.1 mg/mL
fibroblast growth factor 10 (Peprotech), 1 nM gastrin (Sigma-
Aldrich), and 0.1 mg/mL Noggin (Peprotech). Medium was
changed every 2–3 days. Organoids were passaged by mechanical
disruption once a week at an average split rate of 1:11. Imaging
of the organoids was performed using an Olympus CKX41 micro-
scope in combination with a Leica DFC425C camera.
Feline Liver Organoid Differentiation
Feline liver organoids of four donors in similar passage number
(p5–p7) were cultured in cEM for 5 days, after which the medium
composition was changed. In differentiation medium, nicotin-
amide, R-spondin-1, forskolin, and Y27632 were withdrawn and
25 ng/mL BMP7 (Peprotech), 10 mM DAPT (g-secretase inhibitor,
Selleckchem), and 30 mM dexamethasone (Sigma-Aldrich) were
added. Differentiation medium was replaced every other day until
the end of differentiation (day 7).
Measuring Lipid Accumulation in Liver Organoids
with Flow Cytometry
Liver organoids of mouse, human, dog, and cat (four donors per
species) were treated with either 0.4 mM oleate (C18:1) and
0.2 mM palmitate (C16:0) coupled to 12% (w/v) fatty acid-free
BSA (all from Sigma-Aldrich) or with fatty acid-free BSA as vehicle
control for 24 hr (details provided in Supplemental Experimental
Procedures) and then dissociated to single cells with TrypLE select
enzyme (Gibco). Cell suspensions were washed, and an aliquot
was mixed with 0.4% trypan blue and counted on an automated
cell counter (Bio-Rad). Cells were incubated with 0.025 mg/mL
LD450 (lipophilic dye, kindly provided by Christoph Thiele) for
30 min at 37C. Incubations without LD540 served as a negative
control. Cells were washed and resuspended in Hank’s balanced
salt solution with 5 nM Sytox red (Gibco). Cells were analyzed
by flow cytometry on a FACSAria II SORP (BD Biosciences) (Fig-
ure S1). A 635-nm laser with an emission detection of 670/
30 nm was used to detect Sytox red; dead cells were excluded
from analysis. A 532-nm laser with emission detection at 610/
20 nm was used to detect lipid accumulation in cells using
LD540. The voltage was either 619 mV (Sytox red) or 300 mV
(LD540).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, three figures, and two tables and can be found with
this article online at http://dx.doi.org/10.1016/j.stemcr.2017.
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